587
Views
20
CrossRef citations to date
0
Altmetric
Review

Modulators of microglia: a patent review

, , &
Pages 427-437 | Received 07 Aug 2015, Accepted 21 Dec 2015, Published online: 16 Mar 2016
 

ABSTRACT

Introduction: Microglia are highly dynamic immune cells that play a key role in the development, hemostasis and inflammatory response of the central nervous system. These cells could be a valid therapeutic target because of their involvement in the inflammatory scenario in many neuropathological diseases.

Area covered: Many attempts have aimed to act on microglial cells through different approaches, for instance as viral carriers to transfer genetic material, anti-inflammatory drugs to polarize and shift microglia from M1 toward an M2 phenotype, and stem cell therapy.

Expert opinion: The challenge remains to find ways to act selectively on this population in the inflammatory site. Original approaches are genetic targeting or pharmacological therapies that exploit some nanomaterials to deliver promising compounds. These results strongly encourage work aimed to modulate activated microglia, laying the base for treating many neurological diseases.

Article highlights

  • Microglia are highly dynamic immune cells that play a role in the development, hemostasis and inflammatory response of the central nervous system.

  • Many attempts have been made to act on microglia through different approaches able to polarize and shift them from M1 toward an M2 phenotype.

  • The key point remains selective action on these cells in the inflammatory site.

  • Nanomaterials could address this issue, serving as Trojan horses, then acting on the microglia.

  • Several studies (papers and patents) confirm that microglial cells could be a key therapeutic target in the inflammatory scenario of many neuropathological diseases.

This box summarizes key points contained in the article.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.